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Reverse transcriptase-coupled polymerase chain 
reaction (Amplicor HIV-1 Monitor), the branched 
DNA (bDNA) method (Quantiplex HIV-1 RNA) and 
the nucleic acid sequence-based assay (NASBA 
HIV-1 RNA QT) were comparatively evaluated for 
the quantitation of human immunodeficiency vi- 
r u s  type l (HIV-l) RNA in plasma. Among 60 
plasma specimens from HIV-1 infected patients, 
HIV-1 RNA was detected in 56 by Amplicor (sensi- 
tivity, 93.3%), in 41 by bDNA (sensitivity, 68.3%), 
and in 60 by NASBA (sensitivity, 100%). HIV-1 
RNA was not detected by any of these methods 
in 34/34 plasma specimens from HiV-1-seronega- 
tive blood donors (specificity, 100%). The HIV-1 
RNA levels as determined by the different meth- 
ods were correlated significantly. The frequency 
of concordant results (log difference <0.50) was 
80.4% between Amplicor and NASBA, 77.5% be- 
tween Amplicor and bDNA, and 58.6% between 
bDNA and NASBA. After initiation of antiviral 
therapy, HIV-1 RNA level variations observed 
with the three methods were similar. HIV-1 RNA 
levels were inversely correlated with the CD4+ 
T cell counts, whereas no correlation was found 
with HIV-1 p24-antigen levels. When the methods 
were evaluated for reproducibility, coefficients of 
variation ranged from 11% to 40% for Amplicor, 
from 6% to 35% for bDNA, and from 13% to 62% 
for NASBA. Quantitation of HIV-1 RNA in culture 
supernatants from HIV-1 subtype A to H strains 
showed that bDNA can be used to quantitate 
RNA from all HIV-1 subtypes, whereas Amplicor 
failed to detect RNA from subtype A strains and 
NASBA subtype G strains. o 1996 Wiley-Liss, Inc. 
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INTRODUCTION 
Quantitation of human immunodeficiency virus type 
1 (HIV-1) RNA in plasma represents a useful tool for the 
management of patients with HIV-1 infection. Indeed, 
HIV-1 RNA can be detected during all stages of HW-1 
infection [Piatak et  al., 19931. During the asymptomatic 
period, the HIV-1 RNA level in plasma remains stable, 
reflecting an  equilibrium between HIV- 1 replication 
rate and efficacy of immune response [Henrard et al., 
19951. In contrast, an increase in the HIV-1 RNA plasma 
level is correlated with disease progression [Holodniy 
et al., 1991; Semple et  al., 1991; van Kerckhoven et al., 
1994; Verhofstede et al., 19941. Studies carried out on 
patients with long-term non-progressive HN-1 infec- 
tion have shown that very low HIV-1 RNA levels are 
found in these patients, compared with patients with 
progressive HIV-1 disease [Cao et al., 1995; Pantaleo 
et al., 19951. I t  has  also been shown that early in HIT-'- 
1 infection, the HIV-1 RNA level in plasma is predictive 
of the clinical course of the disease [Hogervorst e t  al., 
19951 and that  plasma levels of HN-1 RNA predict 
clinical outcome independently of CD4+ lymphocyte 
counts [Mellors e t  al., 1995,19961. Taken together, these 
data indicate that  the HIV-1 RNA level in plasma could 
represent a more relevant criteria than the CD4+ lym- 
phocyte count for the initiation of antiretroviral 
therapy. 
On the other hand, i t  has been shown that in patients 
treated with anti-retroviral drugs, the efficacy of treat- 
ment seems t o  be correlated with a dramatic decrease 
in the HIV-1 RNA level in plasma, whereas either loss 
of drug activity or treatment discontinuation are associ- 
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bDNA and NASBA procedures for HIV-1 RNA quantita- 
tion in plasma specimens. 
ated with an increase in RNA level [Piatak et  al., 1993; 
Schuurman et  al., 1995; Loveday et al., 1995; Semple et  
al., 1991; O’Brien et  al., 19961. Furthermore, compared 
with other virological markers such a s  HIV-l-p24 anti- 
genemia or HIV-1 proviral DNA burden in peripheral 
blood cells, the HIV-1 RNA level in plasma has been 
found to be the only marker which reflects the downreg- 
ulation of viral replication in lymphoid tissue during 
the course of antiviral therapy [Cohen et al., 19951. 
Therefore, HIV-1 RNA level in plasma can now be con- 
sidered as the most suitable marker to predict disease 
progression and to assess the efficacy of antiretrovi- 
ral therapies. 
Until recently, quantitative reverse transcription- 
coupled polymerase chain reaction (RT-PCR) was used 
to determine the HIV-1 RNA level in plasma. However, 
in-house quantitative RT-PCR procedures, which are 
exceedingly labor intensive, are not convenient for 
large-scale use. They also suffer from laboratory-to-lab- 
oratory variation due t o  the lack of standardization [Lin 
et al., 19941. 
HIV-1 RNA quantitation in plasma can now be car- 
ried out by using commercial assays. The Amplicor HIV- 
1 Monitor assay (Roche Diagnostics Systems, Neuilly, 
France) is based on the RT-PCR technology. The quanti- 
tation procedure relies on Co-amplification of an inter- 
nal RNA standard; amplified products are detected 
thereafter by a nonradioactive detection system 
[hlulder e t  al., 19941. The Quantiplex HIV RNA assay 
(Chiron Diagnostics, Cergy-Pontoise, France) is based 
on branched DNA (bDNA) signal amplification technol- 
ogy. The direct detection of HN-1 RNA involves a series 
of nucleic acid hybridizations. The captured HIV-1 RNA 
target sequences are hybridized with multiple branched 
DNA molecules that  serves as  amplifier. After hybrid- 
ization of enzyme-labeled probes with the amplifier, the 
RNA-probe complex is detected by use of chemilumines- 
cent substrate [Dewar et  al., 1994; Pachl e t  al., 19941. 
The HIV-1 RNA QT assay (Organon Teknika, Fresnes, 
France) involves the nucleic acid sequence-based ampli- 
fication (NASBA) procedure, which is based on isother- 
mal amplification of an HIV-1 RNA target sequence by 
the simultaneous enzymatic activity of avian myelo- 
bastosis vins reverse transcriptase (AMV-RT), T7 RNA 
polymerase and RNase H. In this reaction, RNA se- 
quences serve as  template for the extension of primer 
I, which contains the T7-RNA polymerase recognition 
site, by A.hR’-RT. Extension is followed by degradation 
of the template RNAs by RNase H, synthesis of the 
second DNA strand through extension of primer 2 by 
AMV-RT, and RNA synthesis by T7 RNA polymerase. 
With RNA synthesis the system enters the isothermal 
cyclic phase, resulting in the accumulation of RNA am- 
plificates. Three internal calibrators are  co-amplified 
with the target sequence, and the amplified products 
are detected by electrochimioluminescence after hy- 
bridization with ruthenium-labeled probes [van Gemen 
et  al., 1993a,b]. 
In the present study, we evaluated the Amplicor, 
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MATERIALS AND METHODS 
Plasma Specimens 
Ninety-four blood samples were collected on EDTA 
anticoagulant from 74 subjects, after informed consent; 
these subjects belonged to three groups. The first group 
consisted of 25 consecutively enrolled HIV-1 infected 
patients a t  different stages of HIV-1 infection. One blood 
specimen was studied for each of these patients; nine 
received antiretroviral therapy a t  the time of sampling. 
The second group consisted of 15 HIV-1 infected pa- 
tients followed up after initiation of antiviral therapy: 
one was treated with zidovudine, six were treated with 
zidovudine plus didanosine, and eight were treated with 
foscarnet. A total of 35 samples were obtained from this 
group of patients; The first sample was collected before 
“initiation of treatment and a t  least one other sample 
was collected during the course of the treatment. The 
third group included 34 HIV-1- and HIV-2-seronegative 
volunteer blood donors, Blood samples were centrifuged 
within 2 h r  after venipuncture; plasma was then di- 
vided into aliquots and stored a t  -80°C until use. 
HIV-1 Strains 
Viral isolates representing HN-1  subtypes. A to H 
were cultured in phytohemagglutinin-stimulated pe- 
ripheral blood mononuclear cells (2 X lo6 cells per ml) 
from HIV-1- and HIV-2-seronegative donor. The strains 
were DJ258 and DJ263 (subtype A), IIIB and SF2 (sub- 
type El), ZAM18 and ZAMBO (subtype C), UG2SO and 
UG274 (subtype DI, CM235 and CM241 (subtype E), 
162-3069 and 163-3070 (subtype F), G98 and LBV21- 
7 ?subtype G), and VI557 (subtype HI. Supernatant 
cultures were diluted with a pool of plasmas from blood 
donors and stored a t  -80°C until testing. 
HIV-1 RNA Quantitation 
Amplicor, bDNA, and NASBA assays, carried out ac- 
cording to the manufacturers’ instmctions, are briefly 
described below: 
(i) Amplicor. RNA was extracted from 0.2 ml 
plasma by using a lytic reagent containing guanidine 
thiocyanate (GuSCN) and a known amount of quantita- 
tion standard (QS). QS is a synthetic RNA molecule 
that contains primer binding sites identical to the HN-  
1 target and a unique sequence that  serves as  target 
for a QS-specific probe. HIV-1 and QS RNA molecules 
were precipitated with isopropanol and resuspended 
in a buffer containing carrier RNA. A 142-base pair 
sequence in the gag gene of HN-1 and QS were co- 
amplified with 5’ end-biotinylated primers SK431 and 
SK462. Reverse transcription and PCR were carried 
out in a single reaction by using the thermostable re- 
combinant enzyme rTth DNA polymerase. dUTP was 
incorporated into each amplification t o  serve as  sub- 
strate for AmpErase enzyme (uracil N-glycosylase) to  
prevent carry-over contamination of previously ampli- 
4- 
HrV-1 RNA Quantitation 
fied material. The biotinylated HN-1  and QS amplicons 
were capturcd in separate wells of a microtiter plate 
coated with HN-l-specific and QS-specific oligonucleo- 
tide probes, respectively. To quantify the amplicons over 
a large dynamic range, five-fold serial dilutions of HIV- 
1 and QS amplicons were made in the HN-l-specific 
and QS-specific wells. The bound biotinylated ampli- 
cons were detected with a n  avidin-horseradish peroxi- 
dase conjugate and a chromogenic substrate mixture. 
Absorbance was measured at 450 nm. The HIV-1 RNA 
copy number was calculated from the known input copy 
number of the QS RNA. 
HN-1 virions were pelleted from dupli- 
cate 1.0 ml plasma samples by centrifugation a t  
23,500 x g for 1 hr. Pellets were resuspended in a buffer 
containing proteinase K, lithium lauryl sulfate, and tar- 
get probes complementary to the HN-1 pol gene se- 
quences. Hybridization of target probes with HIV-1 
RNA was obtained by incubation a t  53°C for 20 min. 
The mixture was then centrifuged at 23,500 x g  for 
15 min. A 0.2 ml aliquot of the clarified extract was 
transfemed to  microwells coated with capture probe 
complementary to a sequence of the target probes. The 
RNA-target probe complex was captured on the surface 
of the microwells during incubation overnight a t  53°C. 
The wells were washed and the DNA amplifier mole- 
cules were hybridized to the captured target-probe com- 
plex a t  53°C for 30 min. After subsequent washing, 
alkaline phosphate-labeled probes were hybridized 
with the amplifier bDNA molecules a t  53°C for 15 min. 
After additional washes, the immobilized complex was 
incubated with a chemiluminescent substrate (dioxe- 
tane), and light emission was measured in a lumino- 
meter. The amount of HN-1  RNA in each specimen was 
determined by reference to a standard curve, run in 
parallel with the patient specimens, and that consisted 
of a DNA plasmid a t  four concentrations. With this 
method, the results are expressed as the number of HIV- 
1 RNA equivalents per ml. With the aim of rendering the 
results obtained by the different procedures uniform, we 
considered that one HN-1 RNA equivalent was equal to 
one HIV-1 RNA copy. 
(iii) NASBA. HN-1 RNA was extracted from either 
0.1 or 1.0 ml of plasma by using a lysis buffer containing 
GuSCN. Three synthetic RNA calibrators (&a, Qb, Qc) 
of known high, medium, and low concentration, respec- 
tively, were then added; each RNA calibrator contained 
a short unique sequence differing from the HIV-1 wild 
type. RNA was extracted by using acidified silica, ac- 
cording t o  the procedure described by Boom et  al. 119901. 
HN-1 and calibrator RNA sequences were co-amplified 
by incubation of the extraction product with the primers 
and the enzyme mixture a t  41°C for 90 min. The RNA 
concentration of HIV-1, Qa, Qb, and Qc amplificates 
was measured in four separated aliquots. In each ali- 
quot, the amplified RNA was captured with a biotin- 
labeled oligonucleotide bound to streptavidin-coated 
magnetic beads acting a s  the solid phase, and then 
hybridized with a specific ruthenium-labeled probe 
complenlentary to the HW-1-, Qa-, Qb-, or Qc-specific 
(ii) bDNA. 
295 
sequence. The magnetic beads carrying the hybridized 
amplificate-probe complex were captured on the surface 
of an electrode by means of a magnet. Voltage applied 
to the electrode triggered the electroluminescence reac- 
tion. The light emitted by the ruthenium-labeled com- 
plex was proportional to the amount of amplificate. Cal- 
culation of the relative amount of the four amplificates 
revealed the amount of HIV-1 RNA in the sample. 
The main technical characteristics of Amplicor, 
bDNA, and NASBA are summarized in Table I. L 
Reproducibi l i ty  Determinat ion 
Plasma specimens were prepared by diluting the HN-  
1 III-B strain culture supernatant with a pool of plasma 
samples obtained from blood donors. Two HIV-1 RNA 
levels were tested for reproducibility. One high-level 
plasma specimen was used to test the reproducibility 
of the three quantitation procedures. The low-level 
plasma specimen was a 1:lOO dilution of the high-level 
specimen in the Amplicor and NASBA procedures, and 
a 1:10 dilution of the high-level specimen in the bDNA 
procedure. Plasma specimens were tested five times per 
run in five separate runs for each lot, and two different 
lots were studied for each procedure. For NASBA repro- 
ducibility determination, the high-level plasma speci- 
men was assayed by using 0.1 ml samples, whereas the 
low-level plasma specimen was assayed by using 1.0 
ml samples. The coefficients of variation (CV) were cal- 
culated to determine the within-run, inter-run, and in- 
ter-lot reproducibility for the high-level and low-level 
specimens. 
HIV-1 p24 Antigenemia 
HN-1 p24 antigen level in plasma was determined 
after acid dissociation of immune complexes by the 
Coulter HIV-1 p24 antigen assay (Coultronics, 
Margency, France). Quantitation was carried out using 
a standard curve. A cut-off of 30 dm1 was set for this i-' 
assay. 1- i I 
HIV-1 Subtyping 
HIV-1 was isolated from patients' peripheral blood 
mononuclear cells following standard lymphocyte cocul- 
ture [Jackson et  al., 19901. HIV-1 DNA was extracted 
from cultured cells by using the isoQuick isolation kit 
(Microprobe Corp., Garden Cove, CA). Subtyping was 
performed by the heteroduplex mobility assay [Delwart 
e t  al., 19931. Briefly, DNA amplification by PCR in- 
volved a series of reactions, with 3 p1 of the first round 
reaction product added to  a second round of PCR with 
internally annealing primers. First round primers were 
ED5 and ED12, and second round primers were ES7 
and ES8. Second round amplification yielded a product 
of approximately 700 bp, spanning the V3-V5 region 
of the HIV-1 envelope. For the first round the PCR 
conditions were as follows: 1 cycle a t  94°C for 5 min, 
55°C for 30 sec, and 72°C for 2 min, followed by 29 cycles 
a t  94°C for 15 sec, 55°C for 30 sec, and 72°C for 2 min 
with the final extension a t  72°C for 7 min. The condi- 
tions for the second round were: 1 cycle a t  94°C for 5 
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TABLE I. Technical Characteristics of Amplicor, bDNA, and NASBA 
Assay volume (ml) limit (log copiedml) samples per run time (hour) 
Amplicor 0.2 2.60 12 6 
bDNA 2 x 1.0 4.00 42 24 
NASBA 0.1 or 1.0 2.60a 10 6 
"Lower detection limit for a 1.0 ml plasma sample. This value was 3.60 log copiedml for a 0.1-ml 
plasma sample. 
\ 
Plasma Lower detection Number of  Run 
TABLE II. Reproducibility of Amplicor, bDNA, and NASBA for Quantitation of HIV-1 RNA 
RNA Mean CV Mean CV Mean cv 
level Determination Lot Run copiedm1 SD (%) copiedml SD (%) copiedml SD (5%) 
High Whithin run 1 1 637,780 205,604 32 265,100 43,888 17 1,500,000 331,662 22 
2 355,932 40,756 11 278,120 29,848 11 1,366,000 355,358 ' 26 
3 314,623 94,235 30 290,640 16,704 6 1,140,000 167,332 15 
4 267,463 64,020 24 285,400 28,919 10 1,680,000 414,728 25 
5 463,573 56,540 12 376,060 22,198 6 1,282,000 291,753 23 
2 1 331,019 49,582 15 326,600 61,159 19 2,640,000 403,732 15 
2 410,448 52,804 13 431,680 32,653 8 2,460,000 912,688 37 
' 3 558,146 114,786 21  332,620 53,553 16 2,500,000 355,902 14 
4 592,565 86,439 15 382.680 69,560 18 2,340,000 403,732 17 
5 322,099 72,734 23 455,920 58,575 13 2,720,000 342,052 13 
Inter-run 1 398,295 158,587 40- 299,064 48,558 16 1,393,000 349,998 25 
2 442,855 36,009 3 1  385,900 73,767 19 2,533,333 507,908 20 
Inter-lot 421,030 146,156 35 342,482 75,025 22 1,951,836 718,495 37 
Low Whithin run 1 1  3,924 674 17 47,954 12,443 26 9,140 3,642 40 
2 2,052 560 27 58,308 3,236 7 11,280 7,040 62 
3 2,834 443 16 52,080 13,934 27 11,200 3,346 30 
4 2,486 400 16 53,166 7,076 13 9,880 2,399 24 
5 4,566 682 15 75,826 21,028 28 8,500 4,964 58 
2 1  3,271 1,083 33 69,558 24,166 35 6,660 1,876 28 
2 2,745 858 31 84,496 6,620 8 9,720 4,778 49 
3 4,440 1,120 25 67,730 20,989 31 11,620 4,579 39 
4 4,381 923 21 77,654 6,946 9 8,120 4,203 51 
5 2,752 804 29 99,954 11,794 12 5,200 1,918 37 
Inter-run . 1 3,172 1,082 34 55,467 15,945 29 10,000 4,321 43 
2 3,518 1,170 33 79,858 18,753 23 8,276 4,090 49 
Inter-lot 3,345 1,118 33 67,673 20,971 31 9,138 4,254 47 
Amplicor bDNA NASBA 
min, 55°C for 30 sec, and 72°C for 2 min, followed by 
39 cycles a t  94°C for 15 sec, 55°C for 30 sec, and 72°C 
for 2 min, with the final extension a t  72°C for 7 min. 
The PCR amplification products were detected by elec- 
trophoresis on a 1% agarose gel. Heteroduplex mole- 
cules were obtained by mixing two divergent PCR am- 
plified DNA fragments (the unknown patient strain 
with a plasmid from typed references strains) dena- 
tured a t  96% for 3 min and renatured by rapid cooling 
on ice. The reaction was performed in 100 mM NaCl, 
10 mM Tris HCl (pH 7.8) and 2 mM EDTA in a final 
volume of 8 ~ 1 .  The heteroduplex formation was re- 
solved by electrophoresis analysis a t  200 V for 3 h on 
a nondenaturing 5% polyacrylamide gel in TBE buffer 
(88 mM Tris borate, 89 mM boric acid, 2 mhl EDTA) 
and was detected after staining with ethidium bromide. 
The electrophoretic mobility of the heteroduplexes was 
inversely proportional t o  the sequence divergence of the 
two annealed strands. 
Data Analysis 
Results were expressed as  log HIV-1 RNA copies per 
ml of plasma. The number of HIV-1 RNA copies per 
ml were used for the calculation of the coefficients of 
variation (CV = S.D./mean). Statistical comparison of 
the means were performed by Student's t test. Values 
lower than the detection limit were omitted for the cal- 
culation of means. Significance tests of correlations 
were performed by the standard linear regression 
method. To evaluate the correlation between the HI% 
1 RNA levels and either HIV-1 p24 antigenemia or 
CD4+ cell counts, specimens from the patients who had 
antiviral therapy at the time of testing were omitted. 
We considered as concordant results obtained by two 
methodologies for a given specimen when a log differ- 
ence of ~ 0 . 5  was observed; they were considered as  
highly discordant when the log difference was > L O .  
RESULTS 
Specificity, Sensitivity, and Reproducibility 
Among the 60 plasma specimens collected from HIV- 
1 infected subjects, HIV-1 RNA could be quantitated 
in 56 by Amplicor (sensitivity, 93.3%), in 41 by bDNA 
(sensitivity, 68.3%), and in 60 by NASBA (sensitivity, 
100%). 
Plasma samples collected from HIV-1-seronegative 
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TABLE III. HIV-1 RNA Levels Determined by Amplicor, bDNA, and NASBA in Plasma Specimens From HIV-1 
-infected Patients 
HIV-1 p24 HIV-1 HIV-1 RNA quantitation Patient Disease CD4' cell count 
no. stage (cells/mm3) antigenemia (pg/ml) subtype Amplicor bDNA NASBA 
Group 1 
1 A 456 <30 NDa 3.90 <4.00 3.26 
2 B 260 <30 A <2.60 <4.00 4.89 
3 B 148 <30 B 5.14 5.17 5.39 
4 A 502 ND ND 3.89 <4.00 3.75 
5 C 18 <30 B 4.70 <4.00 3.95 , 
6 A 389 349 ND 5.04 4.88 5.08 
7 B 448 ND B 4.11 <4.00 4.28 
8 Ah 619 57 ND 5.64 4.92 ' 5.60 
9 C 58 34 B 5.74 5.40 5.34 
10 A 284 <30 B 4.85 4.45 4.32 
11 A 1038 <30 ND 5.17 4.08 4.92 
12 B 34 110 B 5.16 4.69 4.86 
13 A 707 <30 ND 4.04 <4.00 3.90 
14 B 225 92 ND 4.52 4.36 4.43 
15 A 49 1 200 - B  4.90 4.30 4.81 
16 A 280 77 B 4.67 4.52 4.57 
17 A 403 ND ND 4.00 <4.00 4.08 
18 B 233 <30 ND 4.32 4.41 4.53 
19 C 35 1140 B 6.52 6.04 5.91 
20 B 442 166 B 5.12 4.85 5.36 
21 B 76 ND ND 5.58 4.95 5.59 
22 A 367 <30 E X2.60 <4.00 3.14 
23 A 3 19 <30 ND 4.90 4.04 4.70 
24 A 201 <30 ND 3.83 C4.00 3.72 
25 A 432 <30 A <2.60 4.04 4.43 
Group 2, first detemination 
1 C 348 1870 B 5.23 5.22 5.76 
2 C 32 110 B 5.35 5.15 5.32 
3 B 203 <30 ND 4.08 <4.00 4.15 
4 C 50 538 ND 5.55 4.70 4.90 
5 C 376 166 B 5.99 5.40 5.79 
6 C 170 209 B 5.87 5.41 5.83 
7 C 256 35 B 4.90 4.08 5.28 
8 C 4 39 ND 6.0 5.82 6.40 
9 C 153 253 B 5.94 6.00 6.00 
10 C 1 <30 B 5.75 5.71 5.87 
11 C 58 128 ND 5.40 5.13 5.40 
12 C 60 153 B 5.53 5.24 5.45 
13 C 2 79 B 5.86 5.38 6.04 
14 C 2 122 B 5.98 5.57 5.94 
15 C 33 1 <30 ND 5.25 4.83 5.29 
'ND, not determined. 
bPrimary infection. 
blood donors were all negative (i.e., copy number < de- 
tection limit) by Amplicor, bDNA, and NASBA, indicat- 
ing that the three techniques had a specificity of 100% 
Data on the reproducibility of the three methods are 
shown in Table II. The within-run CVs ranged from 11 
to 33% for Amplicor, from 6 to 35% for bDNA and from 
13 to 62% for NASBA. In the high-level plasma speci- 
men, the mean within-run CV was 19.6% for Amplicor, 
12.4% for bDN-4 and 20.7% for NASBA; in the low-level 
specimen, the value was 23% for Amplicor, 19.6% for 
bDNA and 41.8% for NASBA. The inter-run CVs ranged 
from 31 to 40% for Amplicor, from 16 to 29% for bDNA 
and from 20 to 49% for NASBA. The inter-lot CVs 
ranged from 22 to 47%, according to the different meth- 
ods. The lowest inter-lot CVs were obtained by b,DNA. 
In the high-level plasma specimen, the inter-lot CVs 
obtained by Amplicor (35%) and NASBA (37%) were 
very similar; in the low-level plasma specimen, how- 
ever, the inter-lot CV obtained by Amplicor (33%) was 
lower than the inter-lot CV obtained by NASBA (47%) 
and was very similar to the inter-lot CV obtained by 
Copy Number Determination in the 
Plasma Specimens 
When we considered the 40 specimens for which HW- 
1 RNA levels were higher than the detection limit of 
each method, the mean HIV-1 RNA levels determined 
by Amplicor, bDNA and NASBA were 5.38 -+ 0.52 log 
copies per ml, 5.03 i 0.55 log copies per ml, and 
5.39 t 0.53 log copies per nil, respectively. The mean 
values significantly differed between Amplicor and 
bDNA ( P  < 0.01) and between NASBA and b-DNA 
(P  < 0.011, whereas no significant difference was ob- 
served between Amplicor and NASBA ( P  > 0.90). 
As shown in Table III, the HIV-1 RNA level could be 
bDNA (31%). 
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TABLE IV. Variation in the HIV-1 RNA Copy Number From Baseline in Patient. Followed up After Initiation of 
Antiviral Therapy 
Deviation of log HIV-1 RNA copy number' Number of days 
Treatment Patient No. after initiation Amplicor bDNA NASBA Mean J 
AZT 3 56 <-1.78b -c -0.48 - 
UT-ddI 1 O d  +0.48 +0.25 -0.10 $0.21 
27 -2.23 < - 0.80b -3.06 -2.64 
4 29 -2.70 <-0.6gb -2.30 -2.50 
5 O' -0.41 -0.10 + o s 1  -0.13 
44 -2.08 <-1.40b -1.41 -1.74 
9 32 -2.54 <-2.00 -2.07 -2.30 
11 O' -1-0.57 +0.50 t0.50 +O52 
15 -2.23 C-1.13b - 1.91 -2.07 
15 32 -1.85 <-0.83b -2.41 -2.13 
Foscarnet 2 6 +0.35 -0.33 -0.06 -0.01 
6 11 -1.57 - 1.33 -0.95 - 1.28 
20 -1.57 -1.21 -1.10 , -1.29 
29 -0.82 -0.41 -0.30 -0.51 
7 15 -0.67 <-0.07 -1.10 -0.88 
8 14 -0.52 -0.67 -0.80 -0.66 
10 12 -0.34 -0.27 $0.07 -0.18 
12 18 -1.79 <- 1.23b -1.41 -1.60 
13 16 +0.11 t0 .13 +0.16 t0 .13 
14 77 -0.18 -0.27 -0.11 -0.18 
aResults for the first sample are  reported in Table III. 
hHIV-l RNA level below the lower limit of detection of the method; these results were omitted for calculation of the mean. 
'Deviation could not be determined since the HIV-1 RNA level was below the lower limit of detection in both plasma specimens. 
dThe first plasma specimen was collected 4 days before initiation of therapy. 
T h e  first plasma specimen was collected 29 days before initiation of therapy. 
The  first plasma specimen was collected 6 days before initiation of therapy. 
determined by NASBA in all the 25 plasma samples 
from the first group of patients, whereas this level could 
not be quantitated in three samples by Amplicor and 
in nine samples by bDNA. Among the 35 samples se- 
quentially collected in the second group of patients, the 
HIV-1 RNA level could be determined in all the samples 
by NASBA, but could not be determined in one sample 
by Amplicor and in 10 samples by bDNA. When we 
compared the HIV-1 RNA levels after initiating anti- 
viral therapy in the second group of patients (Table IV), 
we observed that  in all patients but one (patient no. 31, 
the three methods gave very similar changes in RNA 
levels. In patient no. 3, a pregnant women treated with 
zidovudine, a greater decrease was observed by Ampli- 
cor in comparison with NASBA (>1.78 log vs. 0.48 log). 
Among the 15 patients follo~r-ed up after initiation of 
antiviral therapy, the HIV-1 RNA level variation could 
not be determined precisely in one patient by Amplicor 
and in eight patients by bDN.4 since RNA levels dropped 
below the detection limit. 
Correlation Between Amplicor, bDNA, 
and NASBA 
As shown in Figure 1, a significant linear relationship 
was observed between the HIV-1 RNA levels as  deter- 
mined by the different pairs of methods. We also com- 
pared the frequency of concordant and discordant re- 
sults between the different methods. The results, 
presented in Table V, show that the highest concordance 
was observed between Amplicor and NASBA, and the 
lowest concordance between bDNA and NASBA. 
Relationship to HIV-1 P24 Antigenemia 
As shown in Table VI, significant differences in RNA 
levels, quantitated by Amplicor, bDNA, and NASBA, 
were observed between patients with positive or nega- 
tive HIV-l-p24 antigenemia. However, there was no di- 
rect correlation between the HIV-1 P24 antigenemia 
level and the HIV-1 RNA level as  determined by Ampli- 
cor (r = 0.19, N = 30, P > 0.11, bDNA (r  = 0.21, 
N = 24, P > 0.11, and NASBA- (r = 0.29, N = 33, 
P > 0.11. 
Relationship to CD4+ T Cell Count 
Patients with <200 CD4+ T cells per mm3 had signifi- 
cantly higher levels of HIV-1 RNA in plasma than pa- 
tients with >200 CD4+ T cells per mm3 (Table VI). We 
also observed a negative correlation between the CD4+ 
T cell count and the HIV-1 RNA level as  determined by 
Amplicor (r = -0.45, N = 30, P < 0.011, b-DNA (r = 
-0.63, N = 24, P < 0.011, and NASBA (r = -0.35, 
N = 33, P < 0.05). 
Effect of HIV-1 Subtype 
Among patients of the first group, three were infected 
by a non-B HIV-1 subtype strain: two subtype A and 
one subtype E strains. As shown in Table III, the corre- 
sponding plasma samples could be quantitated by 
NASBA but could not be quantitated by Amplicor 
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Fig. 1. Correlation between Amplicor and bDNA (A), bDNA and 
NASBA (B), and Amplicor and NASBA (C) .  Dashed lines represent 
the lower limits of detection. 
whereas, for two of these plasma specimens, the RNA 
level was below the bDNA detection limit. We therefore 
tested different HIV-1 subtype strains diluted with a 
pool of plasma obtained from HIV-1-seronegative blood 
donors. Differences were observed according to the 
strains tested (Table VII): subtype A strains were not 
detected by Amplicor. We also observed that the copy 
number detected by Amplicor was much lower than the 
copy number detected by bDNA (log difference >1.0) in 
one subtype E and one subtype F strain. Furthermore, 
subtype G HIV-1 RNA could not be detected by NASBA. 
On the other hand, RNA from all the HIV-1 subtypes 
could be detected and quantitated by bDNA. However, 
lower HN-1  RNA levels were measured by bDNA than 
by Amplicor and NASBA for subtype B strains. 
DISCUSSION 
HN-1  RNA level in plasma now constitutes a primor- 
dial criteria for the therapeutic decision in HN-1 infec- 
tion. Therefore, a specific, sensitive, and reproducible 
procedure must be used for this purpose. In the present 
study, we compared the performances of the three cur- 
rently available commercial procedures for HIV-l RNA 
quantikation in plasma, namely, Amplicor, bDNA, and 
NASBA. 
HIV-1 RNA could not be detected in the plasma sam- 
ples of noninfected subjects. Therefore, the three meth- 
odologies were 100% specific. Differences were observed 
in sensitivity, since HIV-1 RNA could not be detected 
by Amplicor and bDNA in respectively 6.7% and 31.7% 
ofthe plasma specimens collected in HIV-1-infected sub- 
jects. However, H N - 1  RNA could be quantitated in all 
these specimens by using NASBA. The defect of sensi- 
tivity observed with bDNA can be explained by the high 
detection limit of this method (4.0 log HIV-1 RNA copies 
per ml), whereas Amplicor and NASBA have similar 
detection limits that are more than 20 times lower than 
the bDNA detection limit. 
The results indicate that  bDNA is the most reproduc- 
ible method. In the high-level plasma specimen, the 
reproductibilities ofAmplicor and NASBA were not very 
different since the mean within-run CVs were about 
20% and the inter-lot CVs about 35%. In the low-level 
plasma specimen, however, the reproducibility of Am- 
plicor was not very different from the reproducibility 
of bDNA since the mean within-run CVs were about 
20% and the inter-lot CVs about 30%, whereas the re- 
producibility of NASBA was lower, as shown by CVs 
higher than  40%. 
It was observed that the genetic variability of HIV-1 
affects the quantitation of HN-1 RNA by the different 
techniques. Indeed, we observed that HlV-1 RNA could 
not be detected by Amplicor, neither in the plasma speci- 
mens from subtype-A infected patients, nor in the cul- 
ture supernatants of subtype A references strains. The 
lack of detection of subtype .4 HN-1 strains by Amplicor 
has already been reported [Todd et al., 1994; Loussert- 
Ajaka et  al., 19951. We also observed that  HIV-1 RNA 
could not be detected by NASBA in the culture superna- 
tants of subtype G HIV-l references strains. Moreover, 
in a defined HIV-1 subtype, inter-strain genetic vari- 
ability could also affect the determination of the RNA 
level since differences were observed between subtype 
E or subtype F strains by using Amplicor. On the other 
hand, HIV-1 RNA from all the subtype reference strains 
could be quantitated by bDNA. Both Amplicor and 
NASBA methodologies are based on aiilplification of a 
target sequence by using a couple of primers, and the 
300 
'J'M3LE V. Differences Between HIV-1 RNA Levels Determined by Amplicor, bDNA, 
and NASBA 
!d&iA compared Number % (95% CI) (no, vf $.pecimens)R log difference - 
<0.50h 31 77.5 (64.6-90.4) 
37.5 (7.6-32.4) 
80.4 (70.0-90.8) 
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'Siiwirrms with RNA level < detection limit were omitted. 
' ' h ' I $ ~ J h  differing by <0.05 log are considered as concordant. 
'ILwínlt, dinering by 0.50-0.99 log are considered as discordant. 
' ~ I J I ~ .  differing by 21.0 log are considered as highly discordant. 
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TA131~1; VI. Relationship Between RNA Levels, HIV-1 p24 Antigenemia, and CD4-k T Cell Counts 
CD4+ T cell count 
Antigenemia (pg/ml) (number/mm3) 
<200 I >200 P Method '30 >30 .P  
5.66 t 0.36 4.87 t 0.69 <.o1 
<.o1 
<.O5 
<.o1 
bDNA 4 .W t 0.61 5.20 ? 0.42 <.O5 
NASBA .f.:jf) t 0.73 5.50 ? 0.53 <.o01 5.43 t- 0.80 
4.79 t 0.46 
4.80 f O.Ï5 
Amplicor 4.61 f 0.69 5.42 f 0.54 
5.43 t 0.35 
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in plasma from patients infected with subtype B HIV- 
1 were possibly underestimated by bDNA. However, 
since i t  has  been reported that bDNA is not affected by 
genetic variability [Todd et  al., 1994,19951, the possibil- 
ity of an  overestimation of subtype B HIV-1 RNA levels 
by the target sequence amplification-based procedures 
such a s  Amplicor and NASBA cannot be excluded. 
Taken together, these data indicate that bDNA is a 
highly reproducible method that allows quantitation of 
RNA from different HN-1 subtypes. However, bDNA 
has a low sensitivity since, in our experience. HIV-1 
RNA could not be quantitated in more than 309 of the 
patient specimens. In particular, HIV-1 RNA could not 
J 
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be quantitated by bDNA in 717 patients followed up 
after initiation of antiretroviral treatment with zido- 
vudine or zidovudine plus didanosine. Therefore, the 
presently available bDNA assay cannot be used for an 
effective follow-up of HIV-1 infected patients with low 
HIV-1 RNA levels. However, according to the manufac- 
turer, a bDNA assay with improved sensitivity (detec- 
tion limit <3.0 log HIV-1 RNA copies per ml) is being 
developed. On the other hand, Amplicor and NASBA, 
both based on target sequence amplification, presented 
comparable performances. These methods were much 
more sensitive than bDNA, but they were less reproduc- 
ible. The use of Amplicor and NASBA can be restricted 
by HIV-1 genetic variability since HIV-1 RNA from 
strains belonging to certain African HIV-1 subtypes 
were not detected by Amplicor or NASBA. In particular, 
Amplicor cannot- be used in patients infected with sub- 
type A HIV-1 strains, whereas NASBA cannot be used 
in patients infected with subtype G HIV-1 strains. 
A significant correlation was found between the HIV- 
1 RNA levels as determined by the different procedures. 
The best correlation was observed between the results 
obtained by Amplicor and NASBA. The highest propor- 
tion of concordant results (i.e., log difference < 0.50) 
was also observed with Amplicor and NASBA, whereas 
the lowest proportion of concordant results was ob- 
served between bDNA and NASBA. Therefore, Ampli- 
cor and Nasba, in addition to the fact that they are both 
based on sequence amplification, can be considered a s  
closely related procedures. 
Similar results were obtained with Amplicor, bDNA, 
and NASBA when the HIV-1 RNA levels were compared 
with the CD4+ T cell counts or the HIV-l-p24 antigen 
levels. The inverse correlation observed between HIV- 
1 RNA levels and CD4+ cell counts, as  well as the 
lack of correlation between HIV-1 RNA and HW-l-p24 
antigen levels, confirm previously reported results 
[Winters et al., 1993; Lin e t  al., 1994; van Kerckhoven 
et al., 19941. These data indicate that  the HIV-1 RNA 
level in plasma, which reflects HN-1  replication in 
lymphoid organs, is correlated with immune impair- 
ment. Therefore, the CD4+ cell count and the HIV-1 
RNA level in plasma constitute complementary mark- 
ers which can be associated advantageously. The higher 
sensitivity of HIV-1 RNA detection in plasma, in com- 
parison with HIV-1 p24 antigen detection [van Kerckho- 
ven et nl., 19941, as well as  the lack of correlation be- 
tween HIV-1 RNA and HIV-1 p24 levels question the 
usefulness of HIV-1 p24 antigenemia for monitoring 
HIV-1 infected patients. 
Similar variations in HIV-1 RNA levels, as  deter- 
mined by Amplicor, bDNA, and NASBA, were observed 
after initiation of antiviral treatment. The only patient 
in which a marked difference in the RNA level decrease 
was observed had a low baseline level. We therefore 
spppose that a reduced accuracy of the methods with 
RNA levels near the detection limit could explain this 
difference. Our results confirm the high decrease (about 
3 (3 log) ofthe I-IIV-1 RNA level in patients treated with 
j ..e combination of zidovudine and didanosine [Shafer 
+ 
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et  al., 19951. I t  has  been reported that foscarnet, an  
anti-cytomegalovirus drug, has ,  antiretroviral activity 
in vitro [Koshida et  al., 19891 and in vivo [Reddy et  al., 
19921. It has also been shown that foscarnet therapy 
decreases HIV-1 RNA level in plasma [Kaiser et al., 
19951. In  the present study, HIV-1 RNA levels were 
sequentially , determined by , Amplicor, bDNA, and 
NASBA in patients who were treated with foscarnet for 
a cytomegalovirus disease. The results obtained by the 
three methodologies are concordant and confirm the 
previously observed anti-HIV-1 activity of foscarnet. 
However, in a high proportion of patients treated with 
antiretroviral drugs, decreases in HIV-1 RNA levels 
could not be precisely determined by using bDNA since 
RNA levels frequently fell below the detection limit, 
indicating that Amplicor. and NASBA are more conve- 
nient procedures than bDNA,for the follow up of pa- 
tients undergoing antiretroviral therapy. 
In a recent report, Revets e t  al. [1996] compared the 
three HIV-1 RNA quantitation procedures and con- 
cluded that  the three assays can be used to  measure the 
HIV-1 RNA copy number. We agree with this conclusion. 
However, our study clearly shows that the performances 
of the presently available tests could be improved either 
by decreasing the,detection limit (bDNA) or by .quanti- 
tating more efficiently the non-B HIV-1 strains (Ampli- 
cor and NASBA). 
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